October 26, 2015

What's Hot & What's Not in Immuno-Oncology LicensingThis web panel discussion, hosted by ShareVault, Defined Health, Pullan Consulting, the Licensing Executives Society and the Biotechnology Industry Organization (BIO), discussed what's exciting and not so exciting in immuno-oncology drug development, and why.

For the live event, biotech licensing and pharmaceutical business development consultant Linda Pullan was joined by four panelists who are business development experts from global pharmaceutical companies, a leading academic cancer center, and a top business development consulting firm. The panelists discussed if it is too late to get into PD1 and other checkpoint inhibitors, how they judge immuno-oncology combinations, if CAR-T can go into solid tumors, the impact of business models on cell therapy, winning strategies for deals in immuno-oncology licensing, and more.If you are developing an immuno-oncology drug or working toward in- or out-licensing one, you will want to hear these perspectives.

request the recording
of the web panel discussion